U.S. Antiviral Drugs Market to Reach USD 23.61 Billion by 2030 Amid Falling COVID-19 Demand and Rising Generic Adoption

The U.S. antiviral drugs market, valued at USD 26.41 billion in 2024, is projected to decline slightly to USD 23.61 billion by 2030, registering a CAGR of -1% according to DataM Intelligence. The market is experiencing a structural shift as demand for COVID-19-specific antivirals declines following reduced hospitalizations and lower infection rates. However, consistent demand for treatments targeting chronic viral illnesses such as HIV, hepatitis B and C, herpes, and influenza continues to sustain market activity.

The rise of generic antiviral drugs and increased focus on affordable healthcare are reshaping market dynamics. While patented antiviral treatments still dominate, a wave of generic launches, expiration of key patents, and expanded access to telehealth and online pharmacies are catalyzing structural transformation. The growing prevalence of HIV-which accounted for nearly 37.7% of U.S. antiviral drug revenue in 2024-remains a critical driver for innovation in combination therapies and single-tablet regimens.

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar

Key Highlights from the Report

➤ U.S. antiviral drugs market valued at USD 26.41 billion in 2024, expected to reach USD 23.61 billion by 2030.
➤ HIV segment dominates with 37.7% share, supported by advanced antiretroviral therapy (ART) regimens.
➤ Branded antivirals hold 61.7% market share in 2024, led by FDA-approved fixed-dose combinations.
➤ Generic antivirals expected to grow at 1.7% CAGR as patents expire and affordability improves.
➤ DNA polymerase inhibitors projected to exhibit fastest growth in hepatitis and herpes treatment.
➤ Hospital pharmacies remain dominant distribution channels; online pharmacies gaining traction with telehealth adoption.

Market Segmentation
By type, branded drugs accounted for 61.7% of 2024 revenue due to their established clinical efficacy and large-scale use in chronic viral therapy. The generic segment, however, is projected to record steady positive growth through 2030, driven by lower costs and increased competition following the expiration of patents for major drugs like efavirenz and tenofovir. Companies like Teva, Mylan, and Sandoz are expanding affordable treatment options accessible through hospital and online channels.

By drug class, reverse transcriptase inhibitors (RTIs) hold the largest market share, forming the backbone of ART regimens for HIV management. DNA polymerase inhibitors are gaining share with their efficacy against hepatitis B and herpes simplex virus (HSV) infections. Continuous FDA approvals-including expanded use of Mavyret for pediatric hepatitis C in June 2025-underscore growing clinical innovation in the space.

By application, HIV continues to dominate due to ongoing treatment needs and government-backed ART programs. Meanwhile, herpes treatment is growing the fastest as diagnosis awareness improves and resistant virus strains drive R&D efforts. Combination therapies with better viral suppression and fewer side effects are helping expand patient adherence and quality of life.

Regional Insights
The U.S. antiviral landscape shows significant adoption variations across regions. East Coast states such as New York and Massachusetts maintain strong ART and hepatitis treatment programs. The Southern states, which face higher rates of chronic infections, exhibit growing demand for generics and public health-driven treatment expansion. The West Coast, particularly California, continues to lead clinical trials and antiviral research collaborations through academic and biotech partnerships.

Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar

Market Dynamics
Market Drivers
High prevalence of chronic infections like HIV and hepatitis B/C sustains long-term antiviral demand. FDA approvals of pediatric and combination regimens improve treatment accessibility. The expansion of telehealth and online pharmacies further enhances drug availability and prescription management.

Market Restraints
Reduced incidence of COVID-19 and influenza has curtailed short-term antiviral use. Moreover, high prices of branded drugs-such as the USD 84,000 cost for a 12-week Sovaldi course-limit affordability. Patient trust, insurance complexities, and reimbursement gaps remain significant barriers.

Market Opportunities
Patent expirations and FDA policies promoting generics create significant affordability opportunities. Ongoing research into drug-resistant strains, pediatric formulations, and combination therapies will stimulate sustainable innovation. The integration of antiviral treatments with digital health tools presents new patient engagement avenues.

Purchase This Exclusive Report at Just USD 4964 Only: https://www.datamintelligence.com/buy-now-page?report=antiviral-drugs-market?utm_source=OpenPR&utm_campaign=Onkar

Reasons to Buy the Report
✔ In-depth forecast of the U.S. antiviral drugs market through 2030.
✔ Analysis of key therapeutic areas including HIV, hepatitis, and herpes.
✔ Insights into emerging generic trends reducing healthcare cost burden.
✔ Evaluation of FDA regulatory developments influencing drug lifecycle.
✔ Competitive intelligence featuring top pharmaceutical players across antiviral categories.

Frequently Asked Questions (FAQs)
◆ What is the projected size and growth rate of the U.S. antiviral drugs market by 2030?
◆ Which antiviral drug class currently dominates the U.S. market?
◆ Who are the key players in the U.S. antiviral drugs industry?
◆ How are generics impacting the pricing and availability of antiviral treatments?
◆ What are the main challenges and growth opportunities for antiviral therapy developers?

Company Insights
F. Hoffmann-La Roche Ltd.

GSK plc.

AbbVie, Inc.

Merck & Co. Inc.

Johnson & Johnson Services, Inc.

Bristol-Myers Squibb Company

Cipla Inc.

Aurobindo Pharma

Dr. Reddy's Laboratories Ltd.

ADARx Pharmaceuticals Inc.

Recent Developments:

June 2025: FDA approved expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

February 2023: Ascend Elements partnered with Honda Motor Co. Ltd. for sustainable lithium recovery from antiviral drug manufacturing supply chains.

Conclusion
The U.S. antiviral drugs market is undergoing transformation amidst declining COVID-specific demand and rising accessibility of generics. Despite a moderate contraction in market value, long-term opportunities remain strong through HIV, hepatitis, and herpes therapies supported by FDA-backed innovation and competitive pricing structures. The transition toward affordable generics, pediatric indications, and online distribution is expected to reshape access, affordability, and compliance. With continuous research and robust industry engagement, the U.S. antiviral drug sector is poised to evolve toward equitable and sustainable healthcare outcomes through 2030.

Contact Us

Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com

About Us

DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.

This release was published on openPR.